| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 14K | 0 | 0 | 0 | 0 | 0 | 67.42M |
| Revenue Growth % | - | -1% | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 14K | 0 | 0 | 0 | 0 | 0 | 67.42M |
| Gross Margin % | 1% | - | - | - | - | - | 1% |
| Gross Profit Growth % | - | -1% | - | - | - | - | - |
| Operating Expenses | 23.8M | 46.84M | 118.79M | 216.54M | 227.29M | 299.51M | 258.62M |
| OpEx % of Revenue | 1699.79% | - | - | - | - | - | 3.84% |
| Selling, General & Admin | 4.88M | 8.46M | 33.89M | 40.94M | 54.55M | 59.4M | 87.11M |
| SG&A % of Revenue | 348.29% | - | - | - | - | - | 1.29% |
| Research & Development | 18.92M | 38.39M | 84.9M | 175.6M | 172.73M | 235.16M | 167.77M |
| R&D % of Revenue | 1351.5% | - | - | - | - | - | 2.49% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 4.95M | 3.74M |
| Operating Income | -23.78M | -46.84M | -118.79M | -216.54M | -227.29M | -299.51M | -191.19M |
| Operating Margin % | -1698.79% | - | - | - | - | - | -2.84% |
| Operating Income Growth % | - | -0.97% | -1.54% | -0.82% | -0.05% | -0.32% | 0.36% |
| EBITDA | -23.73M | -46.73M | -118.63M | -216M | -225.86M | -298.12M | -189.91M |
| EBITDA Margin % | -1695.11% | - | - | - | - | - | -2.82% |
| EBITDA Growth % | - | -0.97% | -1.54% | -0.82% | -0.05% | -0.32% | 0.36% |
| D&A (Non-Cash Add-back) | 51.49K | 111K | 160K | 544K | 1.43M | 1.39M | 1.29M |
| EBIT | -23.78M | -46.84M | -118.79M | -207.74M | -227.29M | -248.99M | -187.46M |
| Net Interest Income | 355K | 498K | 0 | 0 | -2.57M | 0 | 0 |
| Interest Income | 355K | 498K | 0 | 0 | 2.26K | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 2.58M | 0 | 0 |
| Other Income/Expense | 355K | 482K | 683K | 50.15M | -10.29M | 6.6M | 25.5M |
| Pretax Income | -23.43M | -46.36M | -118.1M | -166.39M | -237.58M | -292.91M | -165.69M |
| Pretax Margin % | -1673.43% | - | - | - | - | - | -2.46% |
| Income Tax | 4K | 15K | 444K | -297K | -469K | -601K | 177K |
| Effective Tax Rate % | 0.9% | 0.98% | 1% | 0.95% | 1% | 1% | 1% |
| Net Income | -21.07M | -45.66M | -117.84M | -158.72M | -236.81M | -292.19M | -165.84M |
| Net Margin % | -1504.79% | - | - | - | - | - | -2.46% |
| Net Income Growth % | - | -1.17% | -1.58% | -0.35% | -0.49% | -0.23% | 0.43% |
| Net Income (Continuing) | -23.43M | -46.38M | -118.55M | -166.09M | -237.11M | -292.31M | -165.87M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 7.54M | 6.82M | 24.8M | 528K | 221K | 107K | 0 |
| EPS (Diluted) | -1.17 | -1.29 | -2.87 | -3.72 | -4.48 | -4.47 | -2.33 |
| EPS Growth % | - | -0.1% | -1.22% | -0.3% | -0.2% | 0% | 0.48% |
| EPS (Basic) | -1.17 | -1.29 | -2.87 | -3.72 | -4.48 | -4.47 | -2.33 |
| Diluted Shares Outstanding | 18.06M | 35.88M | 41.04M | 42.69M | 52.86M | 65.41M | 71.08M |
| Basic Shares Outstanding | 18.06M | 35.88M | 41.04M | 42.69M | 52.86M | 65.41M | 71.08M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 26.68M | 68.89M | 345.1M | 350.77M | 451.93M | 496.72M | 386.07M |
| Cash & Short-Term Investments | 25.15M | 67.25M | 338.5M | 340.13M | 437.37M | 482.92M | 371.08M |
| Cash Only | 25.15M | 67.25M | 54.95M | 59.96M | 43.07M | 28.04M | 33.9M |
| Short-Term Investments | 0 | 0 | 283.55M | 280.17M | 394.3M | 454.88M | 337.18M |
| Accounts Receivable | 917K | 140K | 0 | 2.63M | 0 | 0 | 5M |
| Days Sales Outstanding | 23.91K | - | - | - | - | - | 27.07 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 417K | 0 | 14.56M | 13.8M | 0 |
| Total Non-Current Assets | 14.32M | 19.34M | 20.45M | 121.25M | 101.52M | 65.31M | 44.27M |
| Property, Plant & Equipment | 260K | 2.84M | 3.62M | 52.84M | 50.08M | 41.73M | 37.23M |
| Fixed Asset Turnover | 0.05x | - | - | - | - | - | 1.81x |
| Goodwill | 3.74M | 3.74M | 3.74M | 3.74M | 3.74M | 3.74M | 0 |
| Intangible Assets | 8.8M | 8.8M | 8.8M | 0 | 0 | 0 | 0 |
| Long-Term Investments | -46.26K | 243K | 0 | 40.12M | 23.84M | 2.68M | 0 |
| Other Non-Current Assets | 1.52M | 2.97M | 4.3M | 7.04M | 9.72M | 6.82M | 7.04M |
| Total Assets | 41M | 88.23M | 365.56M | 472.02M | 553.46M | 562.03M | 430.34M |
| Asset Turnover | 0.00x | - | - | - | - | - | 0.16x |
| Asset Growth % | - | 1.15% | 3.14% | 0.29% | 0.17% | 0.02% | -0.23% |
| Total Current Liabilities | 6.21M | 14.9M | 28.6M | 43.94M | 56.65M | 69.37M | 52.73M |
| Accounts Payable | 3.43M | 4.29M | 8.66M | 11.59M | 11.25M | 14.93M | 7.44M |
| Days Payables Outstanding | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 781K | 0 | 1.45M | 2.16M | 2.62M | 0 |
| Deferred Revenue (Current) | 223.42K | 0 | 0 | 0 | 0 | 281K | 0 |
| Other Current Liabilities | 223K | 6.85M | 410K | 20.68M | 43.24M | -2.9M | 0 |
| Current Ratio | 4.30x | 4.62x | 12.07x | 7.98x | 7.98x | 7.16x | 7.32x |
| Quick Ratio | 4.30x | 4.62x | 12.07x | 7.98x | 7.98x | 7.16x | 7.32x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 2.48M | 4.91M | 3.58M | 63.6M | 62.79M | 55.27M | 40.43M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 1.7M | 1.1M | 44.46M | 45.17M | 43.15M | 39.58M |
| Deferred Tax Liabilities | 2.46M | 3.21M | 0 | 19.14M | 15M | 10.34M | 0 |
| Other Non-Current Liabilities | 21K | 5K | 2.48M | 0 | 2.62M | 1.78M | 849K |
| Total Liabilities | 8.69M | 19.81M | 32.18M | 107.54M | 119.43M | 124.64M | 93.15M |
| Total Debt | 0 | 2.48M | 2M | 45.91M | 47.33M | 45.77M | 42.65M |
| Net Debt | -25.15M | -64.77M | -52.95M | -14.04M | 4.26M | 17.73M | 8.75M |
| Debt / Equity | - | 0.04x | 0.01x | 0.13x | 0.11x | 0.10x | 0.13x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -88.27x | - | - |
| Total Equity | 32.31M | 68.42M | 333.38M | 364.48M | 434.02M | 437.39M | 337.19M |
| Equity Growth % | - | 1.12% | 3.87% | 0.09% | 0.19% | 0.01% | -0.23% |
| Book Value per Share | 1.79 | 1.91 | 8.12 | 8.54 | 8.21 | 6.69 | 4.74 |
| Total Shareholders' Equity | 24.77M | 61.6M | 308.58M | 363.95M | 433.8M | 437.28M | 337.19M |
| Common Stock | 2.27M | 2.89M | 41K | 45K | 59K | 70K | 71K |
| Retained Earnings | -37.33M | -82.99M | -200.83M | -359.56M | -596.37M | -888.56M | -1.05B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -56K | 0 | 36K | -125K | -1.35M | 2.19M | 558K |
| Minority Interest | 7.54M | 6.82M | 24.8M | 528K | 221K | 107K | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -24.25M | -39.14M | -86.83M | -154.09M | -163.75M | -207.82M | -170.86M |
| Operating CF Margin % | -1732.21% | - | - | - | - | - | -2.53% |
| Operating CF Growth % | - | -0.61% | -1.22% | -0.77% | -0.06% | -0.27% | 0.18% |
| Net Income | -23.43M | -46.38M | -118.55M | -166.09M | -237.11M | -292.19M | -165.87M |
| Depreciation & Amortization | 51K | 111K | 160K | 544K | 1.43M | 1.39M | 1.29M |
| Stock-Based Compensation | 308K | 617K | 23.15M | 35.74M | 46.84M | 54.82M | 67.27M |
| Deferred Taxes | 2.37M | 0 | 17K | -2.51M | -769K | -853K | 0 |
| Other Non-Cash Items | -2.37M | 0 | 556K | -38.38M | 12.61M | 23.15M | -57.01M |
| Working Capital Changes | -1.18M | 6.51M | 7.84M | 16.61M | 13.25M | 5.86M | -16.54M |
| Change in Receivables | -254K | 777K | -277K | 413K | 0 | 0 | -5M |
| Change in Inventory | -1.86M | 0 | -5.52M | 0 | 0 | 0 | 0 |
| Change in Payables | 977K | 7.12M | 14.31M | 13.96M | 15.53M | 10.92M | -18.02M |
| Cash from Investing | -227K | -352K | -284.83M | -18.11M | -114.18M | -44.46M | 176.56M |
| Capital Expenditures | -227K | -352K | -758K | -6.11M | -2.55M | -583K | -221K |
| CapEx % of Revenue | 16.21% | - | - | - | - | - | 0% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -18.42M | 0 | -111.63K | 0 | 0 |
| Cash from Financing | 9.47M | 81.83M | 360.44M | 178.52M | 261.04M | 237.3M | 108K |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | -46K | 18.42M | -1.15M | 0 | 0 | -241K |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -24.48M | -39.49M | -87.58M | -160.2M | -166.3M | -208.41M | -171.08M |
| FCF Margin % | -1748.43% | - | - | - | - | - | -2.54% |
| FCF Growth % | - | -0.61% | -1.22% | -0.83% | -0.04% | -0.25% | 0.18% |
| FCF per Share | -1.36 | -1.10 | -2.13 | -3.75 | -3.15 | -3.19 | -2.41 |
| FCF Conversion (FCF/Net Income) | 1.15x | 0.86x | 0.74x | 0.97x | 0.69x | 0.71x | 1.03x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 4K | 15K | 18K | 20K | 12K | 140K | 359K |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -65.21% | -90.67% | -58.66% | -45.49% | -59.31% | -67.06% | -42.82% |
| Return on Invested Capital (ROIC) | -249.4% | -650.44% | -62.72% | -51.49% | -43.23% | -50.29% | -35.8% |
| Gross Margin | 100% | - | - | - | - | - | 100% |
| Net Margin | -150478.57% | - | - | - | - | - | -245.96% |
| Debt / Equity | - | 0.04x | 0.01x | 0.13x | 0.11x | 0.10x | 0.13x |
| Interest Coverage | - | - | - | - | -88.27x | - | - |
| FCF Conversion | 1.15x | 0.86x | 0.74x | 0.97x | 0.69x | 0.71x | 1.03x |
| Revenue Growth | - | -100% | - | - | - | - | - |
| 2024 | |
|---|---|
| Reportable | 67.42M |
| Reportable Growth | - |
Zentalis Pharmaceuticals, Inc. (ZNTL) reported $26.9M in revenue for fiscal year 2024. This represents a 191793% increase from $0.0M in 2018.
Zentalis Pharmaceuticals, Inc. (ZNTL) grew revenue by 0.0% over the past year. Growth has been modest.
Zentalis Pharmaceuticals, Inc. (ZNTL) reported a net loss of $149.3M for fiscal year 2024.
Zentalis Pharmaceuticals, Inc. (ZNTL) has a return on equity (ROE) of -42.8%. Negative ROE indicates the company is unprofitable.
Zentalis Pharmaceuticals, Inc. (ZNTL) had negative free cash flow of $134.0M in fiscal year 2024, likely due to heavy capital investments.